BLA 761044 · Janssen Biotech
Stelara
Ustekinumab · Injection · Interleukin-12 Antagonist; Interleukin-23 Antagonist
OrphanLast checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Sep 23, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
164
71 Phase 3, 28 recruiting
FAERS reports
103,163
61,436 serious, 6,203 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2026.
Ustekinumab is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. ( 1.1 ) Active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) Moderately to severely active Crohn's disease in adults and pediatric patients 2 years of age and older. ( 1.3 ) Moderately to severely active ulcerative colitis in adults and pediatric patients 2 years of age and older. ( 1.4 ) 1.1 Plaque Psoriasis (PsO) Ustekinumab is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) Ustekinumab is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn's Disease (CD) Ustekinumab is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active Crohn's disease. 1.4 Ulcerative Colitis (UC) Ustekinumab is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.
Mechanism: Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and IL-23 have been...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 28, 2026 Supplement 21 · Efficacy OrphanLetterLabelMedication Guide
- Apr 15, 2026 Supplement 20 · Efficacy OrphanLetterLabel
- Oct 18, 2019 Supplement 3 · Efficacy LetterLabelReview
- Sep 23, 2016 Original approval · Type 3 - New Dosage Form LabelLetterReview
1 products under this application
- STELARA · USTEKINUMAB 130MG/26ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ustekinumab" as an intervention, any sponsor and status, largest first.
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07116967 · 3,040 participants (planned) · Start Sep 22, 2025 · Primary completion Jan 16, 2031
Drug: Deucravacitinib; Ustekinumab · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 411 sites in all
- Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis SubjectsPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT01708629 · 1,881 participants · Start Sep 2012 · Primary completion Aug 2014
Drug: 210 mg brodalumab; 140 mg brodalumab and 2 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 157 sites in all
- P3 Study Brodalumab in Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT01708603 · 1,831 participants · Start Aug 2012 · Primary completion Sep 2014
Drug: 210 mg brodalumab; 140 mg brodalumab and 2 more · For: Moderate to Severe Plaque Psoriasis
Sites: Birmingham, Alabama; Tucson, Arizona; Hot Springs, Arkansas · 153 sites in all
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03466411 · 1,409 participants · Start Apr 13, 2018 · Primary completion Oct 20, 2023
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 6 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Tucson, Arizona · 579 sites in all
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01369355 · 1,282 participants · Start Sep 13, 2011 · Primary completion Jun 10, 2015
Drug: Placebo SC; Placebo IV and 3 more · For: Crohn's Disease; Colitis; IBD and 1 more
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 220 sites in all
- A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe PsoriasisPivotal-lookingCompleted
Centocor Research & Development, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00307437 · 1,230 participants · Start May 2005 · Primary completion Dec 2006
Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Ustekinumab (CNTO 1275) 45 mg and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 62 sites in all
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseasePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03926130 · 1,158 participants · Start Jul 23, 2019 · Primary completion Aug 23, 2023
Drug: Mirikizumab; Mirikizumab and 4 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Guntersville, Alabama · 580 sites in all
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque PsoriasisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02826603 · 1,114 participants · Start Jun 22, 2016 · Primary completion Jul 9, 2018
Drug: Secukinumab; Ustekinumab · For: Plaque Psoriasis
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 154 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective14,942
- off label use12,880
- product dose omission issue10,242
- fatigue6,966
- psoriasis6,617
- pain6,322
- crohn^s disease5,993
- arthralgia5,902
- rash5,714
- product use issue5,463
- headache5,377
- condition aggravated5,316
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 34 |
| 2010 | 339 |
| 2011 | 836 |
| 2012 | 1,456 |
| 2013 | 1,849 |
| 2014 | 1,704 |
| 2015 | 5,305 |
| 2016 | 4,517 |
| 2017 | 6,660 |
| 2018 | 8,727 |
| 2019 | 10,236 |
| 2020 | 13,325 |
| 2021 | 7,743 |
| 2022 | 9,895 |
| 2023 | 10,036 |
| 2024 | 9,237 |
| 2025 | 7,214 |
| 2026 | 4,050 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stelara* (Ustekinumab)
2024 spending
$3.38B
Beneficiaries
24,754
132,865 claims
Per beneficiary
$136,463
$26,534.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,106,356,248 |
| 2021 | $1,567,482,458 |
| 2022 | $2,339,082,716 |
| 2023 | $2,987,778,600 |
| 2024 | $3,378,017,374 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. · N Engl J Med 2024 · Multicenter Study, Randomized Controlled Trial
- Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T, Koletzko S, Kannengiesser K, et al. · Dtsch Arztebl Int 2020 · Meta-Analysis, Review
- Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.
Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, et al. · J Dermatolog Treat 2022 · Systematic Review
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, et al. · Lancet 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.